Cel­gene antes up $195M more to stay close to For­ma, adding neu­rode­gen­er­a­tion fo­cus

What­ev­er Cel­gene $CELG learned dur­ing its lengthy col­lab­o­ra­tion with For­ma Ther­a­peu­tics must have been promis­ing. The big biotech is dou­bling down on For­ma, ex­tend­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER